Zydus launches India’s first indigenously developed aflibercept biosimilar Anyra
News by Aliceblue News Desk
19 Feb 2026
Introduction
Leading pharmaceutical company launches Anyra™, India’s first Aflibercept 2 mg biosimilar, for treatment of wet AMD, diabetic macular edema, diabetic retinopathy, and other retinal eye conditions.
Also Read: KNR Constructions bags massive ₹2,163 Cr ECR elevated corridor project
Share price movement of Zydus Lifesciences
On February 19, 2026, Zydus Lifesciences Ltd opened at ₹923.65, up 1.51% from its previous close of ₹910.05. The stock reached a high of ₹923.65 (1.51%) and a low of ₹908.30. By 11:51 AM, it traded at ₹909.55, down 0.05%, with a market cap of ₹91,522.01 crore.
Zydus Launches ANYRA™ Biosimilar Aflibercept
Zydus Lifesciences Ltd. launched Anyra™, India’s first indigenously developed Aflibercept 2 mg biosimilar, to treat wet AMD, Diabetic Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, and mCNV.
The launch addresses vision impairment caused by chronic retinal diseases. Anyra™ provides affordable anti-VEGF therapy for patients requiring repeated intravitreal injections across India. The product supports improved treatment adherence and reduced blindness risk.
Zydus has signed agreements with Regeneron Pharmaceuticals and Bayer. The company holds India’s largest biosimilar portfolio with over 13 biologics, covering end-to-end development, clinical trials, manufacturing, and regulatory approvals.
Stock performance of Zydus Lifesciences for period of 1 week, 6 months, and 1 year
Zydus Lifesciences Ltd declined 1.18% over the past week, fell 7.96% in six months, and gained 2.09% over the past one year.
Also Read: Hexaware Technologies launches open RapidX platform with Replit AI integration; check what it means
Shareholding pattern of Zydus Lifesciences
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.10% | 7.30% | 7.10% |
| DII | 11.10% | 10.90% | 11.10% |
| Public | 6.90% | 6.80% | 6.70% |
About Zydus Lifesciences
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) is a global healthcare company, innovating to address unmet medical needs and create healthier, happier communities worldwide.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Zydus Lifesciences Ltd share price rising today?
A: Zydus Lifesciences Ltd gained after launching Anyra™, India’s first Aflibercept 2 mg biosimilar, for treatment of wet AMD and other retinal conditions.
Q: What is Zydus Lifesciences Ltd’s main business focus?
A: Zydus Lifesciences Ltd develops and manufactures pharmaceuticals, biologics, and healthcare products, addressing unmet medical needs globally.
Q: What are the 52-week high and low of Zydus Lifesciences Ltd stock?
A: Zydus Lifesciences Ltd stock has a 52-week high of ₹1,059.00 and a low of ₹797.05.
News Author
Aliceblue News Desk
